The Role of Immunoglobulin-G Subclasses and C1q in De Novo HLA-DQ Donor-Specific Antibody Kidney Transplantation Outcomes

Background Anti–HLA-DQ antibodies are the predominant HLA class II donor-specific antibodies (DSAs) after transplantation. Recently, de novo DQ DSA has been associated with worse allograft outcomes. The aim of this study was to determine the further complement-binding characteristics of the most harmful DQ DSA. Methods Single-antigen bead technology was used to screen 284 primary kidney transplant recipients for the presence of posttransplantation DQ DSA. Peak DSA sera of 34 recipients with only de novo DQ DSA and of 20 recipients with de novo DQ plus other DSAs were further analyzed by a modified single-antigen bead assay using immunoglobulin (Ig)-G subclass-specific reporter antibodies and a C1q-binding assay. Results Compared with recipients who did not have DSA, those with de novo persistent DQ-only DSA and with de novo DQ plus other DSAs had more acute rejection (AR) episodes (22%, P=0.005; and 36%, P=0.0009), increased risk of allograft loss (hazards ratio, 3.7, P=0.03; and hazards ratio, 11.4, P=0.001), and a lower 5-year allograft survival. De novo DQ-only recipients with AR had more IgG1/IgG3 combination and C1q-binding antibodies (51%, P=0.01; and 63%, P=0.001) than patients with no AR. Furthermore, the presence of C1q-binding de novo DQ DSA was associated with a 30% lower 5-year allograft survival (P=0.003). Conclusions The presence of de novo persistent, complement-binding DQ DSA negatively impacts kidney allograft outcomes. Therefore, early posttransplantation detection, monitoring, and removal of complement-binding DQ might be crucial for improving long-term kidney transplantation outcomes.

[1]  W. Suki,et al.  Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. , 2012, Kidney international.

[2]  G. Klintmalm,et al.  Donor‐specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with Chronic rejection and graft loss after liver transplantation , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  C. Roufosse,et al.  De Novo DQ Donor-Specific Antibodies Are Associated With a Significant Risk of Antibody-Mediated Rejection and Transplant Glomerulopathy , 2012, Transplantation.

[4]  P. Nickerson,et al.  Evolution and Clinical Pathologic Correlations of De Novo Donor‐Specific HLA Antibody Post Kidney Transplant , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  S. Sutherland,et al.  Complement‐fixing donor‐specific antibodies identified by a novel C1q assay are associated with allograft loss , 2012, Pediatric transplantation.

[6]  D. Tyan,et al.  Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. , 2011, Human immunology.

[7]  G. Klintmalm,et al.  High Mean Fluorescence Intensity Donor‐Specific Anti‐HLA Antibodies Associated With Chronic Rejection Postliver Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  E. Woodle,et al.  Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition , 2011, Transplantation.

[9]  P. Archdeacon,et al.  Summary of FDA Antibody‐Mediated Rejection Workshop , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  S. Busque,et al.  C1q-Fixing Human Leukocyte Antigen Antibodies Are Specific for Predicting Transplant Glomerulopathy and Late Graft Failure After Kidney Transplantation , 2011, Transplantation.

[11]  G. Berry,et al.  Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  J. Friedewald,et al.  The Complexity of Human Leukocyte Antigen (HLA)-DQ Antibodies and Its Effect on Virtual Crossmatching , 2010, Transplantation.

[13]  J. Lunz,et al.  Antihuman leukocyte antigen–specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific crossmatches. , 2010, Archives of pathology & laboratory medicine.

[14]  R. Gaston,et al.  Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[15]  P. Halloran,et al.  De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  P. Reinke,et al.  Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts , 2009, Transplantation.

[17]  P. Terasaki,et al.  “Natural” Human Leukocyte Antigen Antibodies Found in Nonalloimmunized Healthy Males , 2008, Transplantation.

[18]  Junchao Cai,et al.  Human Leukocyte Antigen Class II DQ Alpha and Beta Epitopes Identified From Sera of Kidney Allograft Recipients , 2008, Transplantation.

[19]  P. Terasaki,et al.  The Importance of Anti‐HLA‐Specific Antibody Strength in Monitoring Kidney Transplant Patients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  R. Colvin,et al.  Banff '05 Meeting Report: Differential Diagnosis of Chronic Allograft Injury and Elimination of Chronic Allograft Nephropathy (‘CAN’) , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  M. Franco,et al.  Post‐Transplant Anti‐HLA Class II Antibodies as Risk Factor for Late Kidney Allograft Failure , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  F. Claas,et al.  Human Leukocyte Antigen Antibodies and Human Complement Activation: Role of IgG Subclass, Specificity, and Cytotoxic Potential , 2004, Transplantation.

[23]  G. Opelz,et al.  SKEWING OF PRETRANSPLANT ANTI-HLA CLASS I ANTIBODIES OF IMMUNOGLOBULIN G ISOTYPE SOLELY TOWARD IMMUNOGLOBULIN G1 SUBCLASS IS ASSOCIATED WITH POORER RENAL ALLOGRAFT SURVIVAL , 2004, Transplantation.

[24]  M. Fishbein,et al.  Antibody‐Mediated Rejection Criteria – an Addition to the Banff ′97 Classification of Renal Allograft Rejection , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  M. Brüggemann,et al.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q , 1988, The Journal of experimental medicine.

[26]  N. Lachmann,et al.  Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. , 2006, Clinical transplants.

[27]  G. Iaria,et al.  Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry. , 2006, Clinical transplants.

[28]  C. Haisch,et al.  Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. , 2006, Clinical transplants.